| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
DMU-212 (0.3125-40 μM) prevents human melanoma cells A375, MeWo, Bro, and M5 from growing [1]. In A375 cells, DMU-212 (30–50 μM; 24 hours) causes apoptosis, ERK activation, and the overexpression of cell cycle inhibitors [1].
|
|---|---|
| ln Vivo |
In human ovarian cancer xenograft models, DMU-212 (50 mg/kg; ig; three times weekly; for 14 days) inhibits the growth of tumors [2].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: A375 cells, MeWo cells, M5 cells, Bro cells Tested Concentrations: 0.3125 μM, 0,625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM Incubation Duration: 96 hrs (hours) Experimental Results: Inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC50=0.5 μM for A375 and Bro and IC50= 1.25 μM for MeWo and M5 cells). Cell Cycle Analysis[1] Cell Types: A375 cells Tested Concentrations: 20 μM, 30 μM, 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: Caused a marked increase in the levels of p21, p53 and cyclin B1 proteins with a concomitant decrease in the levels of cyclin A2. Western Blot Analysis[1] Cell Types: A375 cells Tested Concentrations: 20 μM, 30 μM, 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: Significant upregulated Bax, caspase 3 and caspase 9 protein levels, while diminished the levels of the anti-apoptotic protein Bcl-2. Apoptosis Analysis[1] Cell Types: A375 cells Tested Concentrations: 10 μM, 20 μM Incubation Duration: 24 hrs (hours), 36 hrs (hours) Experimental Results: Induced apoptosi |
| Animal Protocol |
Animal/Disease Models: 6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts[2]
Doses: 50 mg/kg Route of Administration: po (oral gavage), three times a week, for 14 days Experimental Results: Lowered tumor burden. |
| References |
[1]. Vasilis Pericles Androutsopoulos, et al. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015 Aug;24(8):632-4.
[2]. Hanna Piotrowska, et al. DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer. Biomed Pharmacother. 2014 May;68(4):397-400. |
| Molecular Formula |
C18H20O4
|
|---|---|
| Molecular Weight |
300.35
|
| CAS # |
134029-62-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
COC1C=C(/C=C/C2C=CC(OC)=CC=2)C=C(OC)C=1OC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 20 mg/mL (66.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (6.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3294 mL | 16.6472 mL | 33.2945 mL | |
| 5 mM | 0.6659 mL | 3.3294 mL | 6.6589 mL | |
| 10 mM | 0.3329 mL | 1.6647 mL | 3.3294 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
